Latest filing published 19 Oct 2026 for Ultragenyx Pharmaceutical Inc., €96k.
This profile gathers the share dealings of Howard Horn across 2 companies, led by Ultragenyx Pharmaceutical Inc. and Vir Biotechnology, Inc. In total, 19 filings cover trades dated from 17 February 2022 to 15 October 2026.
Sales make up the whole of the open-market record (13 sales, €1.5M). Outside the open market, there are 6 share grants. Since January 2026: no purchases and 6 sales on the market.
The record was last updated on 19 October 2026 with an open-market sale (€96k) in Ultragenyx Pharmaceutical Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations